论文信息 - Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity - 字舞流文

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

A. Stracciari | P. Zinzani | P. Cortelli | M. Guarino | S. Mondini | R. D’Angelo | R. Rinaldi | F. Bonifazi | Umberto Pensato | A. Farolfi | B. Casadei | M. Nicodemo | L. Spinardi | L. Faccioli | Michele Dicataldo | F. Rondelli | Giulia Amore | R. Santoro | Susanna Sammali | M. Dicataldo

[1] P. Zinzani,et al. Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy , 2021, Annals of clinical and translational neurology.

[2] Michael R. Green,et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma , 2021, Blood.

[3] H. Zetterberg,et al. SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4] Matt P. G. Morgan,et al. Neurological updates: neurological complications of CAR-T therapy , 2020, Journal of Neurology.

[5] S. Nikiforow,et al. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. , 2020, JAMA neurology.

[6] P. Cortelli,et al. COVID‐19–Associated Encephalopathy and Cytokine‐Mediated Neuroinflammation , 2020, Annals of neurology.

[7] Anurag K Singh,et al. CAR T cells: continuation in a revolution of immunotherapy. , 2020, The Lancet. Oncology.

[8] M. Kersten,et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) , 2019, Haematologica.

[9] H. Hinson,et al. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment , 2019, Current Treatment Options in Neurology.

[10] C. Jacobson,et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. , 2019, Brain : a journal of neurology.

[11] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12] C. Turtle,et al. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies , 2018, CNS Drugs.

[13] L. Deangelis,et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[14] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[15] M. Wurfel,et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[16] A. Cavanna,et al. Paligraphia and written jocularity in Gilles de la Tourette syndrome , 2011, Movement disorders : official journal of the Movement Disorder Society.